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Significance of Anti-HLA Antibodies 
on Adult and Pediatric Heart Allograft 
Outcomes
Massimo Mangiola1*, Marilyn Marrari1, Brian Feingold2 and Adriana Zeevi1*
1 Division of Transplant Pathology, Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA, 
2 Pediatric Cardiology, The Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA
As methods for human leukocyte antigens (HLA) antibody detection have evolved 
and newer solid phase assays are much more sensitive, the last 15 years has seen a 
renewed focus on the importance of HLA antibodies in solid organ transplant rejection. 
However, there is still much controversy regarding the clinical significance of antibody 
level as depicted by the mean fluorescence intensity of a patient’s neat serum. Emerging 
techniques, including those that identify antibody level and function, show promise for 
the detection of individuals at risk of allograft rejection, determination of the effectiveness 
of desensitization prior to transplant, and for monitoring treatment of rejection. Here, we 
review current publications regarding the relevance of donor-specific HLA antibodies 
(DSA) in adult and pediatric heart transplantation (HT) with graft survival, development 
of antibody-mediated rejection and cardiac allograft vasculopathy (CAV). The negative 
impact of DSA on patient and allograft survival is evident in adult and pediatric HT 
recipients. Many questions remain regarding the most appropriate frequency of 
assessment of pre- and posttransplant DSA as well as the phenotype of DSA memory 
vs. true de novo antibody using large multicenter adult and pediatric cohorts and state-
of-the-art methodologies for DSA detection and characterization.
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inTRODUCTiOn
Heart transplantation (HT) has become an accepted therapy for adult and pediatric patients with 
end-stage heart failure. Despite improved immunosuppression regimens, rejection remains the 
most common cause of death in the first 5 years after HT. Both cellular and humoral immune-
mediated processes that can damage the allograft are primarily directed against human leukocyte 
antigens (HLA). Antibodies against HLA can be found in patients prior to transplantation 
after exposure to foreign HLA through blood transfusion, pregnancy, previous transplant, and 
use of homograft tissue during surgery for some congenital heart defects. Ventricular assist 
devices (VAD) have also been implicated in the development of HLA antibodies, termed 
allosensitization. Exposure to donor HLA after HT may also induce de novo production of 
donor-specific HLA antibodies (DSA). The impact of circulating HLA antibodies on heart 
allografts has been the focus of many investigations and reviews. The introduction of solid 
phase assays (SPA) based on the luminex single antigen bead assay (SAB) has improved the 
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sensitivity and specificity of HLA antibody detection; however, 
it also introduced new challenges for assay interpretation and 
determining its clinical relevance (1).
Identification of DSA enables the clinician to make informed 
decisions regarding acceptance of the organ and the choice 
of immunosuppression (2). Presence of DSA is not always 
considered a contraindication but rather a risk factor for organ 
transplantation success (3). Optimizing transplantation of allo-
sensitized candidates is challenging and program specific. The 
main challenge with the new SPA technology is decision-making 
regarding donor organ acceptance based solely on antibody 
strength determined by mean fluorescence intensity (MFI) (2–5). 
The threshold for accepting a donor for a sensitized patient may 
vary depending on the patient’s clinical status, antibody level, and 
protocols available for antibody removal therapy. Considering 
the SPA modification to detect complement-fixing antibodies 
(C1q-SAB) has reduced the estimated incompatible donor pool 
in highly sensitized patients (6). Optimizing transplantation of 
allosensitized candidates using SAB and C1q-SAB methodology 
to prioritize the assignment of unacceptable antigens has allowed 
transplantation of highly allosensitized patients across the DSA 
barrier with survival rates comparable to DSA− heart transplant 
recipients (5).
Titration of sera prior to SAB testing has emerged as a more 
accurate way to assess the true level of DSA as compared to 
MFI value of undiluted sera (7). Furthermore, titration studies 
provide better estimates of responsiveness to antibody removal 
therapies (8).
Recognition that some preformed antibodies are against 
denatured HLA antigens with very little clinical relevance 
may also impact the search for an acceptable donor (4, 9). The 
assignment of unacceptable antigens has been greatly improved 
also by incorporating patterns of epitope reactivity and history 
of sensitizing events. Recognizing the limitations and advan-
tages of current available methods for antibody determination, 
quantitation and function has facilitated the introduction of 
the virtual crossmatch (VXM) in thoracic transplantation. 
Previously, the need for prospective crossmatch (XM) in 
sensitized patients was associated with longer waitlist duration 
and increased mortality (10). Although VXM is widely used for 
organ allocation, its validity highly depends on how accurate 
and current is the information on patient sensitization events 
and comprehensive DNA-based HLA typing of prospective 
donors as antibodies can be made against every possible poly-
morphic HLA target antigen (2–5).
ReLevAnCe OF DSA On OUTCOMeS
In this report, we focus on a short review of the current state-
of-the-art regarding the role of DSA in adult and pediatric HT 
as determined by the following outcome measures: graft survival 
(GS), development of antibody-mediated rejection (AMR), 
and cardiac allograft vasculopathy (CAV) (Tables  1 and 2). 
Although we limit this review to the last 6 years, the retrospective 
nature of some studies may influence the relevance of DSA on 
clinical outcomes due to the use of less sensitive testing methods. 
Furthermore, we considered separately the role of DSA on adult 
and pediatric clinical outcomes to highlight potential similarities 
and differences in the two cohorts.
ADULT HT
Graft Survival
The prevalence of allosensitization in heart transplant candidates 
increased with the introduction of SPA for screening for HLA 
antibodies (11) (Table 1). Nevertheless, the risk for poor GS has 
remained a significant finding even in the more sensitive SPA 
testing era (11, 12). The presence of non-cytotoxic HLA antibod-
ies identified by SAB was associated with high risk of death, early 
graft failure, and late cellular- and antibody-mediated rejection; 
these findings underscore the need for using sensitive Luminex 
platform SPA to accurately determine the presence of circulating 
HLA antibodies (12). Detection of Class I DSA pretransplant was 
a predictor of short-term but not long-term survival as compared 
to non-DSA (13). In this study limiting the testing on pretrans-
plantation, the authors could not identify the impact of persistent 
vs. transient DSA and of de novo DSA on clinical outcomes.
De novo antibody production and its role in cardiac allograft 
survival has been described in several studies (14–16). In a ret-
rospective adult cohort, de novo DSA was associated with poor 
patient survival (HR = 3.198), while de novo and persistent DSA 
was worst (HR = 4.351) (14). Similarly, patients with persistent 
de novo, mostly Class II DQ-specific DSA, had worse survival 
(15). The 15-year survival was highest in patients who never 
developed DSA vs. those that developed DSA posttransplanta-
tion (70 vs. 47%), and patients with late de novo DSA appearing 
more than 1  year post transplantation had poorest survival 
(16). Thus, determining the presence of DSA pretransplant for 
risk assessment and monitoring for persistent and de novo DSA 
posttransplant provide the most comprehensive information for 
clinical management.
Antibody-Mediated Rejection
The challenges of AMR diagnosis post HT have been addressed 
by many single-center studies and consensus conferences. 
In the current era, diagnosis of this clinically important entity 
has been improved by standardized classification of histologic 
and immunologic changes in endomyocardial biopsies (EMB) 
(17) and by advances in the detection of HLA antibodies. 
Although not required for diagnosis of pathologic AMR 
(pAMR), the detection of HLA antibodies pre- and post-
transplantation has been helpful for risk stratification for the 
development of AMR and for guiding treatment strategies 
(18). Patients with positive VXM defined in the presence of 
DSA >1,500 MFI by SAB had a higher incidence of AMR 
and cell-mediated rejection. Similar outcomes were observed 
with positive flow crossmatch (FXM) suggesting that SAB MFI 
>1,500 can be used as surrogate for FXM (19). Increased risk 
for a positive complement-dependent cytotoxicity (CDC) XM 
and early AMR was observed in patients with persistent C1q+ 
DSA (20). However, patients who had DSA but lost the C1q 
reactivity posttransplant did not develop early AMR, and the 
strength of neat sera on SAB did not predict C1q  reactivity. 
In contrast, high titer DSA (>1:16) has been associated with 
TAbLe 1 | Cited publications from the last 6 years (2010–present) showing the impact of HLA antibody on heart transplantation in adult recipients.
Reference number of patients 
(study period)
Method DSA GS AMR CAv Comments
Gandhi  
et al. (19)
85 (August 2006–
January 2010)
CDC-AHG PRA/XM, 
Flow XM, SAB
All CDC XM−; DSA+ (MFI 
>1,500), n = 11 (13%):  
Class I = 2, Class II = 6, 
Class I + II = 3
(n = 80 for biopsy) 
AMR: 7/11 DSA+
CMR ≥ 1R/1A: 9/11 DSA+ vs. 
48/69 DSA−/weak; DSA MFI 
>1,500 associated with increased 
incidence of AMR and CMR
Smith et al. (14) 243 (October 1995–
July 2004)
SAB (8.8 ± 2.5) 57 dnDSA
Class II = 48 (42/48 DQ)
Poor GS
p = 0.0001 (HR = 4.35)
29% 5 y; 55% 
10 y
DnDSA risk for poor GS and CAV
Ho et al. (16) 950 (January 1995–
December 2009)
CDC T and B, SAB 
(mean number of 
sera tested per 
patient = 24 ± 9)
221 dnDSA 1 y, 118 dnDSA 
>1 y, 460 no HLA-Ab
GS 52%, p < 0.005; 
GS 48%, p < 0.001; 
GS 70%
23 DSA and non-DSA increased in 
rejection
Loupy et al. (29) 196 (1985–2009) SAB 20 very late rejection (VLR 
>7 y)
CAV grade VLR, 
2.06 vs. 0.76 in 
control
VLR associated with severe CAV
Hodges et al. 
(15)
762 (November 2005–
August 2011)
Luminex  
Screen, SAB
15 AMR (14/15 dnDSA) 1.8 y mean survival 
after AMR treatment
15 Late cardiac AMR with dnDSA
Zeevi et al. (20) 15 (8 pediatric, 7 
adult)
SAB, SAB-C1q 35 DSA in 14 patients:  
Class I = 4, Class II = 2, 
Class I + II = 8
1st month post-Tx: 
7/7 cAMR+ are 
DSA+/C1q+; 4 
cAMR-free, DSA+/
C1q− (p < 0.005)
Persistent C1q+ DSA post-Tx 
associated with early clinical AMR
Potena  
et al. (11)
173 (2000–2005) CDC/PRA, Luminex 
Screen
Pre-Tx 32 Ab+ Class I = 28, 
Class II = 16, Class I + II = 12
Survival
65% for Ab+
82% for Ab−
9/37 with biopsy were 
HLA-Ab+, pAMR >2
Raess et al. (13) 272 (1989–2010) CDC-PRA/XM, 
Luminex screen, SAB, 
SAB-C1q
DSA 26 (9.6%), Class I = 14, 
Class II = 5, Class I + II = 7, 
C1q+ DSA = 2
Overall survival: 80% 
(1 y), 68% (5 y)
SAB Class I DSA+: 
62% (1 y), 50% (5 y)
SAB Class I DSA−: 
87% (1 y), 73% (5 y)
Fatal pAMR = 6, all 
≤1 month post-Tx
(n = 245) CAV-
free survival: 96% 
(1 y), 86% (5 y)
ACR-free survival: 38% (1 y), 
30% (5 y); pre-Tx HLA Ab status 
affected short-term survival but 
had no effect on long-term survival/
rejection
Topilsky  
et al. (27)
51 (January 2004–
December 2009)
SAB; Flow XM for 30 
patients
All CDC-XM−; DSA+ 17 
(33%): Class I = 4,  
Class II = 11, Class I + II = 2
36 (71%) with 
Grade 1 CAV
CAV analysis done for patients with 
only Class II DSA; pre-Tx Class 
II DSA may give higher risk of 
accelerated CAV: DSA+ 100% vs. 
DSA− 64.2% at 4 y
Tible et al. (22) 111 (October 2009–
September 2010)
SAB, 150 paired DSA 
and EMB
47/150 DSA+, Class I = 
40.4%, Class II = 40.4%, 
Class I + II = 19.2%
37 MI and CD68 associated with 
DSA+
Frank et al. (28) 109 (February 1996–
June 2011)
SAB, 330 paired DSA 
and EMB
51/112, Class I = 5,  
Class II = 26, Class I + II = 20
24 (22%): 40% 
DSA+, 13% 
DSA−
33% with CAV pre-Tx DSA+; Class 
II DSA, IF C4d+, and MI high risk 
for failed allograft with CAV
(Continued )
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Reference number of patients 
(study period)
Method DSA GS AMR CAv Comments
Coutance  
et al. (24)
20 (November 2006–
February 2013)
Luminex Screen, SAB 19/20 tested were dnDSA+ 50% after 1 y Late AMR (>1 y 
post-Tx)
Prognosis for late AMR poor 
despite aggressive therapy
O’Connor  
et al. (12)
12,858 (June 2004–
March 2013); UNOS 
database
CDC-PRA, Flow-PRA PRA ≥ 10%, Class I: 
CDC+ = 227, Flow+ = 2,243, 
Class II: CDC+ = 126, 
Flow+ = 2,218
PRA ≥ 10%: 
HR = 1.24 (95% CI 
1.12–1.36)
Percent Ab+ patients increased 
from 2005 to 2011 as use of flow 
increased; pre-Tx PRA ≥ 10% by 
Flow associated with increased risk 
of graft loss
Svobodova 
et al. (21)
264 (April 2005–
December 2012; 
mean follow-up 
39 months, range 
19–66)
CDC-PRA/XM; SAB, 
SAB-C1q
DSA = 28 (11%):  
Class I = 18, Class II = 3, 
Class I + II = 7, C1q+ 
DSA = 4
90% (1 y), 79% (5 y) 19 (7%) 31 (12%) 74 patients (28%) with 83 instances 
of ACR grade ≥ Banff 2; pre-Tx 
DSA and elevated peak CDC-PRA 
were strongest predictors of AMR
Frank et al. (23) 44 (2005–2011) SAB-C1q paired with 
EMB C4d stain
C1q+ DSA in 82% with graft 
dysfunction
18/44 died or 
retransplanted
16/17 C4d+ IF had 
C1q+ DSA; 24 C1q+ 
DSA were C4d-IF
Better concordance of C4d+ IF 
with C1q DSA as compared to 
IgG DSA
Loupy et al. (25) 40, failing grafts SAB AMR = 19
Clerkin  
et al. (26)
689 (January 2004–
December 2013, 
follow-up through 
October 2015)
Luminex SAB and/or 
CDC screen
Overall: n = 29 (42.6%);  
early AMR: n = 22 (51.1%); 
late AMR: n = 7 (28.0%)
Decreased post-AMR 
survival in patients with 
late vs. early AMR: 80 
vs. 93%, 1 y; 51 vs. 
73%, 5 y (p < 0.05)
n = 68 (9.9%): 43 early 
(<1 y post-Tx), 25 late 
(>1 y post-Tx)
No difference in 
prevalence early 
AMR vs. late 
AMR (p = 0.51); 
accelerated de 
novo CAV in late 
AMR + graft 
dysfunction 
(50% at 1 y, 
HR = 5.42, 
p = 0.009)
Graft dysfunction increased in 
late AMR group (56.0 vs. 25.6%, 
p = 0.01)
Ab, antibody; ACR, acute cellular rejection; AHG, anti-human globulin; AMR, antibody-mediated rejection; C1q, complement component 1q; C4d, complement component 4d; CAV, cardiac allograft vasculopathy; CDC, complement-
dependent cytotoxicity; CMR, cell-mediated rejection; XM, crossmatch; DSA, donor-specific HLA antibodies; dnDSA, de novo donor-specific HLA antibody; EMB, endomyocardial biopsies; GS, graft survival; HR, hazard ratio; IF, 
immunofluorescence; MFI, mean fluorescence intensity; MI, microcirculation inflammation; pAMR, pathologic AMR; post-Tx, posttransplant; PRA, panel-reactive antibodies; pre-Tx, pretransplant; SAB, Luminex single antigen bead 
assay; VLR, very late rejection; y, year(s); HLA, human leukocyte antigens.
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TAbLe 2 | Cited publications from the last 6 years (2010–present) showing the impact of HLA antibody on heart transplantation in pediatric recipients.
Reference number of patients 
(study period)
Method DSA GS AMR CAv Comments
Rossano et al. 
(31)
3,534 (October 1987–
May 2004, follow-up 
through May 2008), 
UNOS database
CDC-PRA/XM most 
commonly used 
PRA >10% = 387 (11%);  
9% XM+
Median graft survival
PRA >10% = 7.1 y
PRA 1–10% = 9.6 y
PRA 0% = 9.8 y
Decreased long-term GS in 
patients with PRA >10%
Irving et al. (38) 59, mean post-Tx 
follow-up 5.1 y (range 
0.7–18.5 y)
Luminex screen/SAB N = 4 (7%): 1 transient  
Class I, 3 persistent 
Class II
DSA+: 1/4 functioning, 
2/4 retransplanted, and 
1/4 died (7 y post-Tx)
DSA+: 2/4 (50%);  
non-DSA+: 1/15 (7%); 
no Ab: 5/40 (13%)
DSA+: 3/4 (75%); 
non-DSA+: 1/15 
(7%); no Ab: 3/40 
(7.5%)
Severe cellular rejection (≥3R) 
n = 3 (5.1%), all DSA−
Chin et al. (42) 18 (June 2007–
February 2009)
CDC-XM, SAB, SAB-C1q, 
Flow CXM
SAB-IgG DSA:  
Pre-Tx 61.1%,  
Post-Tx 55.5%;  
SAB-C1q DSA: Pre-Tx 
21.4%, post-Tx 35.7%
94% (1 y), 82% (2 y) Within 1st month: 
n = 5 (27.7%),  
all post-Tx SAB-C1q+ 
DSA
SAB-C1q assay may better 
predict early AMR
Mahle et al. (32) 1,904 (January 1993–
December 2008)  
Pediatric Heart 
Transplant Study Group
CDC-PRA most commonly 
used
PRA ≥ 10% = 397 
(15.8%);  
PRA ≥ 50% =  
189 (7.6%)
1 y patient survival: 
PRA ≥ 50%, 73 vs. 
90% for PRA <10%
No CAV association 
with pre-Tx Ab
No association of PRA with 
time to 1st rejection or CAV
Ho et al. (16) 108 (January 2000–
December 2009)
CDC-PRA, SAB PRA >10%
Class I = 9%
Class II = 14%
87% GS in CDC− vs. 
33% CDC+ after 7 y
Correlation between AMR and 
presence of CDC- or SPA-
detected DSA
Scott et al. (34) 101 (2004–2008) CDC-PRA, FLOW PRA >25% decreased 
GS vs. patients with 
PRA <25%
n = 12: 33% with PRA 
>80% vs. 13% with 
PRA <80%
Peng et al. (44) 60 (October 2005–
January 2011)
FLOW-PRA, SAB, 183 
paired DSA and C4d
6 (3/6 XM+) Correlation between C4d+ in 
EMB and DSA >6,000 MFI
Daly et al. (58) 134 (January 1998–
January 2011)
CDC-AHG PRA, Luminex 
SAB; XM+ patients 
received preoperative 
plasmapheresis + IVIG
12 XM+ (9%)
T+/B+ = 8
T−/B+ = 2
T+/B not tested = 2
No significant 
difference in GS for 
XM+ (n = 3, 25%) vs. 
XM− (n = 12, 10%)
1 yr post-Tx:  
XM+ = 6 (50%), 
XM− = 2 (2%) 
(p < 0.001)
Serious infection higher 
in XM+ vs. XM− (50 vs. 
16%, p = 0.005); shorter 
time to 1st infection in XM+ 
(p = 0.001)
Asante-Korang 
et al. (35)
70 (January 2005– 
July 2013)
Luminex PRA, SAB, 
Flow-XM; desensitization 
performed in patients with 
PRA >10%
PRA >10% = 14 (20%) Overall patient survival: 
92.9% in sensitized 
group vs. 80.4% in 
non-sensitized
Freedom from AMR 
or rejection grade 
≥2R/3A: 71.4% in 
sensitized vs. 64% in 
non-sensitized
Freedom from 
CAV: 93% for 
sensitized vs. 91% in 
non-sensitized
12/14 high PRA patients had 
reduced Ab levels following 
desensitization; no significant 
differences in outcomes 
between desensitized patients 
and those with no Ab
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Reference number of patients 
(study period)
Method DSA GS AMR CAv Comments
Chen et al. (36) 25 (January 2008–
June 2010)
PRA and SAB, 195 samples 12/25 dnDSA No impact short-term 
survival
Majority of dnDSA within 1 y
Irving et al. (47) 108 (1996–2009) SAB, 691 samples 43 DSA (58% persistent)
Class I = 30%
Class II = 47%
Class I + II = 23%
9/14 with graft loss had 
persistent DSA
9/10 with CAV 
DSA+; 6/9 DSA 
persistent
Persistent DSA associated 
with poor outcome and CAV
Godown  
et al. (39)
121 (1987–2014), 
mean follow-up 4.1 y
Flow, Luminex,  
all were XM−
dnDSA: 40 (33%)
Class I = 24%
Class II = 50%
Class I + II = 26%
Multiple factors influence DSA 
development; DSA seen more 
frequently in patients with prior 
sensitizing events
Ware et al. (43) 66 (January 2009–
September 2013)
SAB 27 DSA+ (4 XM+) No impact DSA level associated 
with pAMR2, 3
No impact Negative predictive value of 
DSA testing for absence of 
pAMR
Tran et al. (37) 105 (January 2002–
December 2012, 
follow-up 0.13–10.8 y)
SAB (5 times first year 
and yearly after)
45 (43%) DSA
Class I = 20%
Class II = 62.2%
Class I + II = 17.8%
5 y GS 72.4% DSA− 
vs. 21% DSA+
CAV 36% DSA+ vs. 
13% DSA−
DSA+ had 2.5 times more 
rejection events per year 
compared to DSA−
Thrush  
et al. (40)
1,596 (January 2010–
December 2014),  
Pediatric Heart 
Transplant Study 
database
Unknown 33 deaths (16%)  
post-AMR 
development; 
short-term patient/
GS lower for patients 
with treated AMR 
(p = 0.004, p = 0.001, 
respectively); patient 
survival post-AMR 
diagnosis: 88% 1 y, 
77% 3 y
179 (11%), freedom 
from AMR: 88% 1 y, 
82% 3 y
AMR often concurrent with 
ACR
Ab, antibody; ACR, acute cellular rejection; AHG, anti-human globulin; AMR, antibody-mediated rejection; C1q, complement component 1q; C4d, complement component 4d; cAMR, clinical AMR; CAV, cardiac allograft 
vasculopathy; CDC, complement-dependent cytotoxicity; XM, crossmatch; DSA, donor-specific HLA antibodies; dnDSA, de novo donor-specific HLA antibody; EMB, endomyocardial biopsies; GS, graft survival; HR, hazard ratio; IF, 
immunofluorescence; pAMR, pathologic AMR; post-Tx, posttransplant; PRA, panel-reactive antibodies; pre-Tx, pretransplant; SAB, Luminex single antigen bead assay; SPA, solid phase assays; y, year(s); MFI, mean fluorescence 
intensity; HLA, human leukocyte antigens.
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complement-fixing reactivity (7, 20) and has been used to deter-
mine unacceptable HLA antigens for sensitized candidates (5). 
DSA determination by SPA and elevated peak panel-reactive 
antibodies (PRA) were independent predictors of pAMR in an 
adult cohort of heart transplant recipients (21). In this study 
focusing on pretransplant samples, increasing numbers of DSAs 
and the mean cumulative MFI of DSAs were associated with 
risk of AMR, and the subset of C1q-reactive DSAs were less 
informative (21). Pathologic classification of AMR in 37 EMB 
correlated with circulating DSA and endothelial activation (22). 
The proportion of DSA+ EMB varied according to pAMR 
grade, and pAMR2 was associated with 100% DSA positivity 
(22). The clinical significance of DSA level as depicted only by 
MFI of neat serum is still controversial, and currently multiple 
approaches are proposed to capture the DSA level and function, 
including serum titration and complement-binding assays. A 
better concordance was observed between C1q+DSA and C4d 
immunofluorescence (IF)+ staining in EMB as compared with 
total IgG DSAs and C4d IF+ in EMB among 44 recipients (40 
vs. 24%, p = 0.02) (23). A majority (82%) of patients with graft 
dysfunction had circulating C1q+ DSAs (23). However, not all 
patients with circulating C1q+DSA had C4d IF+ staining on 
EMB, suggesting that the presence of C1q+DSA may precede 
the development of pAMR or be due to the low sensitivity of 
C4d IF staining (23).
Prognosis after late AMR (defined as AMR >1  year post-
transplant) was poor in 20 recipients despite aggressive treatment 
with immunosuppression, and fulminant CAV was a common 
condition (24). DSA was present in all tested patients (n = 19) 
with a median cumulative MFI at diagnosis >10,000; most of the 
patients had de novo DSA (24). Antibody-mediated injury and 
immune-mediated coronary arteriosclerosis were the causes of 
late graft failure in a recent study of 40 explanted heart allografts 
(25). AMR was observed in 47.5% failing heart allografts, includ-
ing 40% of patients in whom unrecognized previous episodes of 
subclinical AMR occurred years before allograft loss. Among 
the 19 patients with AMR, 15 were tested for DSA, and 93% had 
circulating DSA at the time of allograft failure. The immuno-
dominant DSA was Class II in 11/14 DSA+, and the median DSA 
MFI was 5,000 (25). In contrast, only 37% of patients without 
AMR features at the time of allograft failure had circulating DSA 
as compared to the AMR group (p < 0.001), and the median DSA 
MFI was 1,250 (25). In a retrospective cohort study spanning 
over 10 years, the timing of AMR (early vs. late) was associated 
with GS and CAV (26). Patients were tested at the time of biopsy 
for circulating DSA either by CDC (before 2010) or SAB (post 
2010). Graft dysfunction was less frequent in early AMR, while 
late AMR with graft dysfunction showed rapid development of 
de novo CAV despite aggressive treatment and also increased risk 
of death (26).
Cardiac vasculopathy
Cardiac allograft vasculopathy continues to remain a limiting 
factor in long-term survival of heart transplant recipients, and 
there is increasing evidence of the negative impact of circulat-
ing DSA on the development and severity of CAV. Patients with 
DSA had significantly higher rates and a shorter mean time to 
CAV and increased severity of CAV as compared to patients 
without DSA (27, 28). Patients with very late rejection and 
circulating DSA with evidence of intravascular macrophages 
had an increased risk of severe CAV as compared to patients 
without DSA (29).
PeDiATRiC HT
Graft Survival
Allosensitization and GS in pediatric HT recipients have been 
evaluated in large single- (30) and multicenter datasets (31, 32) 
(Table 2). Pediatric patients with PRA >10% had earlier-onset 
graft vasculopathy (30) and worse graft and patient survival 
than did patients with PRA <10% (31, 32). Elevated PRA 
was an independent risk factor for worse long-term GS (31). 
Furthermore, significant allosensitization (PRA >50%) at list-
ing was associated with a more than twofold increased risk of 
death within the first transplant year (32). These large patient 
cohorts that were transplanted over a period of 18  years may 
have underestimated the rate of allosensitization because the 
methodology for PRA screening evolved from a less sensitive 
cell-based method to the more sensitive SPA. In addition, the 
SPA may have also increased the need for prospective XM due 
to an increased use of VXM (33).
In a more recent study patients with PRA >25% had signifi-
cantly (p = 0.004) decreased survival compared to those with PRA 
<25% (34). In contrast, the outcome of allosensitized pediatric 
patients with PRA >10% who were desensitized was not different 
than non-sensitized recipients (35).
Assessments of GS in the presence of DSA show somewhat 
mixed findings, perhaps related to the duration of follow-up. 
Although short-term GS was not impacted by the presence of 
DSA in one pediatric study (36), the 5-year survival was signifi-
cantly better in patients without DSA in another pediatric cohort 
(72 vs. 21%) (37). While uncommon, the presence of de novo DSA 
posttransplantation, especially toward Class II HLA, was associ-
ated with increased graft loss (38).
Multiple factors appear to play a role in development of de 
novo DSA in pediatric HT including prior sensitizing events, 
older age, African-American race, and donor death from gunshot 
wound (39). Knowledge of risk factors for the development of de 
novo DSA in pediatric recipients is likely to be important to guide 
the frequency of monitoring for HLA antibodies (39).
Antibody-Mediated Rejection
Current understanding of AMR after HT is largely derived 
from adult studies. Using the Pediatric Heart Transplant Study 
database, the reported incidence of AMR was 11% (among 1,596 
recipients), and patient and GS were lower for those with AMR 
(40). Risk factors associated with AMR included PRA >10% at 
HT, a positive CDC XM, and congenital heart disease, suggesting 
allosensitization related to the use of homografts (40).
The proportion of AMR-free patients was much higher among 
patients with only solid phase-detected DSA vs. those with CDC-
detected DSA (41). Similarly, using the C1q assay, which detects 
only complement-fixing antibodies, the presence of C1q fixing 
DSA prior to or early after HT had a positive predictive value of 
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100%, while absence of C1q fixing DSA had a negative predictive 
value of 100% for AMR (42). In another analysis, the presence 
of circulating DSA had 93% sensitivity, 62% specificity, 24% 
positive predictive value, and 99% negative predictive value for 
biopsy diagnosis of AMR in pediatric recipients (43). In addition, 
higher levels of circulating DSA measured by MFI correlated with 
pAMR severity (43). The authors proposed that DSA monitoring 
provides a non-invasive tool to tailor the frequency of biopsy 
surveillance (43). Others have used an institution-specific MFI 
threshold value for DSA of >6,000 that strongly correlated with 
C4d deposition on EMB with high negative predictive value 
(97%) and specificity (95%) (44). Both studies emphasized the 
advantage of following DSA in asymptomatic pediatric patients, 
given the value of early detection of AMR (43, 44).
Similar to findings for renal transplantation (45), sensitized 
recipients with persistent posttransplant DSA with complement-
fixing ability appear to be at high risk for AMR (20, 42, 46).
Cardiac vasculopathy
Overall, DSA+ patients (preformed or de novo) had significantly 
higher rates of CAV compared with DSA− patients. By 5 years, 
the rate of CAV-free survival was 25% for DSA− vs. 0% for DSA+ 
(37). Persistent DSA was associated with poor outcome and 
development of CAV (47).
TReATMenT
Desensitization is aimed to increase the donor pool by either 
reducing or eliminating HLA allosensitization or by facilitating 
transplant by reducing the DSA burden. Desensitization treat-
ment targets critical components of the humoral response to 
either achieve a negative crossmatch pretransplant or to reduce 
the impact of DSA in positive crossmatch transplants. At low titer, 
antibody reduction can be achieved with plasma exchange and 
IVIG. The use of B cell suppression agents (rituximab), plasma 
cell depletion agents (bortezomib), or inhibitors of complement 
activation (eculizumab) is usually limited to highly sensitized 
patients. The current literature in adults is not abundant, mostly 
observational, with small cohorts, short follow-up, and with 
inconsistent treatment methodologies (48–53). In 21 highly 
sensitized patients, the use of plasmapheresis (PP), IVIG, rituxi-
mab, and cyclophosphamide resulted in comparable long-term 
survival when compared to the low sensitized and unsensitized 
cohorts (53). A recent experience with bortezomib and PP showed 
that about 50% of the patients had a calculated PRA reduction 
and were transplanted with a negative crossmatch (48, 52). One 
year follow-up showed 100% survival and 74% freedom from 
rejection (48, 52). In a smaller cohort of patients transplanted 
across a positive crossmatch and treated with eculizumab and 
ATG, 1-year survival was 89%, and freedom from rejection was 
75% (52). In patients treated for AMR, Class I HLA antibodies 
demonstrated a statistically significant response to bortezomib, 
whereas Class II responded poorly (51).
In pediatric HT, requiring a negative prospective crossmatch 
increases the waiting time and more importantly the waitlist mor-
tality (10). Allosensitization is most significant among children 
with certain forms of congenital heart disease due to the use of 
homograft during prior surgeries. Also, blood transfusions and 
VAD use are common causes of allosensitization. Current litera-
ture for pediatric heart transplant desensitization is even more 
limited than in the adult cohort (54–58). Desensitization was 
carried out successfully with bortezomib and PP in a pediatric 
setting (54). Furthermore, in a single-center retrospective study 
in a large cohort of patients, all sensitized patients received PP or 
plasma exchange preoperatively. If the cytotoxic XM was posi-
tive, PP was continued. Patients with negative XM did not receive 
additional PP and IVIG posttransplant (58). Hemodynamically 
significant AMR occurred in 50% of patients transplanted across a 
positive XM vs. 2% of the XM-negative cohort (58). Additionally, 
incidence of serious infection was higher in patients transplanted 
across a positive crossmatch (58). Antibody depletion therapies 
were also used in management of AMR in pediatric patients. 
Decreased DSA MFI in 21 patients treated with PP correlated 
with good clinical outcome (55). In another small study, addition 
of bortezomib to PP and rituximab treatment resulted in a rapid 
decline in DSA and reversal of AMR without significant side 
effects (56).
SUMMARY
The negative impact of DSA on patient and allograft survival is 
evident in adult and pediatric HT recipients. Allosensitization 
depicted by PRA >10% using cell based (prior era) or SPA 
(current era) is associated with poor outcome in both cohorts. 
Furthermore, similar risk factors were identified in adults and 
pediatric recipients for the development of posttransplant DSA 
including sensitizing events pretransplant, ECMO, need for 
mechanical support, non-compliance, and African-American 
race. In adults, but not in pediatrics, female gender (prior preg-
nancies) was also associated with a higher risk for development 
of de novo DSA. In children, exposure to homografts as part of 
surgical repair for some forms of congenital heart disease increase 
their risk for allosensitization and AMR.
Many questions remain regarding the most appropriate fre-
quency of assessment of pre- and posttransplant DSA as well as 
the phenotype of DSA memory vs. true de novo antibody using 
large multicenter adult and pediatric cohorts and state-of-the-
art methodologies for DSA detection and characterization. The 
observation that early vs. late AMR in HT may have different 
prognosis and responses to treatment emphasizes the need to 
assess the risk of sensitization pretransplantation and to follow 
by routine monitoring of DSA posttransplant.
The ongoing multicenter clinical collaborative studies sup-
ported by National Institute of Health in adult and pediatric HT 
will hopefully provide answers to many remaining questions 
regarding the impact of preformed and de novo DSA on clinical 
outcomes and the efficacy of various modalities for desensitiza-
tion and treatment of AMR.
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